2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 176

Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both
Abstract Number: 419

Comparative Dynamics of Rheumatoid Arthritis Disease Activity and Disease Severity Measures Using Rarbis, Ciras and DAS28 in a Population Based Cohort of Patients with RA
Abstract Number: 2265

Comparative Effects of Raloxifene and Bisphosphonate on Bone Mineral Density and Osteoporotic Fracture Outcomes in Rheumatoid Arthritis Patients
Abstract Number: 2853

Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases
Abstract Number: 2428

Comparative Study of Rheumatoid Arthritis Disease Activity Indices in Two Populations of Meteor Database
Abstract Number: 2400

Comparing a Tapering Strategy to the Standard Dosing Regimen of TNF Inhibitors in Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity
Abstract Number: 1536

Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Abstract Number: 2243

Comparison Between Two Diclofenac Diethylamine Gel Formulations, 1.16% Vs 2.32%: Is It Only Increasing the Strength of the Active Ingredient Enough?
Abstract Number: 1119

Comparison High Intensity Laser Therapy and Wrist Splint in the Treatment of Lateral Epicondylitis
Abstract Number: 1428

Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis
Abstract Number: 553

Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Abstract Number: 440

Comparison of C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) with Estimated Glomerular Filtration Rate (eGFR) in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 96

Comparison of Cardiovascular Risk Factor Management in Patients with RA and Matched Non-RA Patients
Abstract Number: 2616

Comparison of Characteristics of Ankylosing Spondylitis in Association with Familial Mediterranean Fever with Those of Typical Ankylosing Spondylitis
Abstract Number: 826

Comparison of Classification Criteria for Gout Using Monosodium Urate Crystal Identification By a Certified Examiner As the Gold-Standard in a Large Multi-National Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].